149 related articles for article (PubMed ID: 35559914)
1. The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey.
Trapani D; Lengyel CG; Habeeb BS; Altuna SC; Petrillo A; El Bairi K; Hussain S; Mazher SA; Elfaham EM; Curigliano G; Khan SZ
J Cancer Policy; 2021 Jun; 28():100285. PubMed ID: 35559914
[TBL] [Abstract][Full Text] [Related]
2. Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011.
Chavarri-Guerra Y; St Louis J; Bukowski A; Soto-Perez-de-Celis E; Liedke PER; Symecko H; Moy B; Higgins M; Finkelstein DM; Goss PE
Breast; 2017 Feb; 31():197-201. PubMed ID: 27894048
[TBL] [Abstract][Full Text] [Related]
3. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.
Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM
Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V
JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791
[TBL] [Abstract][Full Text] [Related]
5. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
Blackwell K; Gligorov J; Jacobs I; Twelves C
Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
[TBL] [Abstract][Full Text] [Related]
6. Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets.
Lammers P; Criscitiello C; Curigliano G; Jacobs I
Pharmaceuticals (Basel); 2014 Sep; 7(9):943-53. PubMed ID: 25232798
[TBL] [Abstract][Full Text] [Related]
7. The Global Landscape on the Access to Cancer Medicines for Breast Cancer: The ONCOLLEGE Experience.
Lengyel CG; Habeeb BS; Altuna SC; Trapani D; Khan SZ; Hussain S
Cancer Treat Res; 2023; 188():353-368. PubMed ID: 38175353
[TBL] [Abstract][Full Text] [Related]
8. The global landscape of drug development of trastuzumab biosimilars.
Trapani D; Curigliano G
J Cancer Policy; 2021 Jun; 28():100273. PubMed ID: 35559916
[TBL] [Abstract][Full Text] [Related]
9. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
[TBL] [Abstract][Full Text] [Related]
10. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
Whalen J
Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
[TBL] [Abstract][Full Text] [Related]
11. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
12. Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal.
Sharma A; Kaplan WA; Satheesh G; Poudyal IP; Gyawali P; Neupane D; Bhandari PM; Malla M; Sapkota S; Mishra SR
Glob Heart; 2021 May; 16(1):38. PubMed ID: 34040951
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab in Breast Cancer Treatment: The Era of Biosimilars.
Peliçário Vargas B; Sari MHM; Ferreira LM
Anticancer Agents Med Chem; 2022; 22(14):2507-2516. PubMed ID: 35236272
[TBL] [Abstract][Full Text] [Related]
14. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
Paplomata E; Nahta R
Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars for breast cancer.
Migliavacca Zucchetti B; Nicolò E; Curigliano G
Expert Opin Biol Ther; 2019 Oct; 19(10):1015-1021. PubMed ID: 31248290
[No Abstract] [Full Text] [Related]
16. Integrating trastuzumab biosimilars and HER2-directed therapies into HER2-positive breast cancer management.
Cuellar S
Am J Manag Care; 2020 Mar; 26(2 Suppl):S32-S40. PubMed ID: 32282173
[TBL] [Abstract][Full Text] [Related]
17. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
Hara F; Tajima K; Tanabe K
Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
[TBL] [Abstract][Full Text] [Related]
18. Availability and affordability of anticancer medicines in Iran based on WHO/HAI standard survey methods.
Varmaghani M; Elyasi S; Mojahedian MM; Ghavami V; Borhani B; Javan-Noughabi J; Sarafraz S
Support Care Cancer; 2022 Dec; 31(1):89. PubMed ID: 36574075
[TBL] [Abstract][Full Text] [Related]
19. The evolution of biosimilars in oncology, with a focus on trastuzumab.
Nixon NA; Hannouf MB; Verma S
Curr Oncol; 2018 Jun; 25(Suppl 1):S171-S179. PubMed ID: 29910660
[TBL] [Abstract][Full Text] [Related]
20. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Li J; Wang S; Wang Y; Wang X; Wang H; Feng J; Zhang Q; Sun T; Ouyang Q; Yin Y; Liu Y; Geng C; Yan M; Jiang Z
Oncologist; 2017 Nov; 22(11):1333-1338. PubMed ID: 28798274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
